Clinical Trial Update: A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab in combination with trametinib and dabrafenib in advanced melanoma has completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Pembrolizumab (pembrolizumab)
• Trametinib (trametinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma, Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-01